Archives
-
Sodium Picosulfate in Gut–Liver–Brain Research
2026-09-09
A translational framework for using Sodium Picosulfate as a defined gastrointestinal perturbation in chronic constipation, hepatic encephalopathy, and regional neuroinflammation studies—without confusing bowel effects with therapeutic benefit.
-
MLKL Polymerization and Lysosomal Permeabilization
2026-09-09
The reference study identifies lysosomal membrane permeabilization as a mechanistic intermediate between MLKL polymerization and necroptotic cell death. Its experiments place lysosomal cathepsin B release, rather than plasma membrane rupture alone, at the center of a protease-dependent execution pathway.
-
Pepstatin A in Cathepsin D Assay Design
2026-09-08
Pepstatin A is an aspartic protease inhibitor that can function as a mechanistic stress test in cathepsin D and autophagy research. This article explains how to interpret pharmacological inhibition in ischemia/reperfusion endothelial models, select controls, and avoid overclaiming pathway causality.
-
Protease Inhibitor Cocktail: Assay Reliability
2026-09-08
Learn how Protease Inhibitor Cocktail EDTA-Free, SKU K1007, can protect protein endpoints in cytotoxicity, proliferation, phosphorylation, and cell-lysis workflows without adding EDTA to divalent-cation-sensitive assays. This scenario-based guide separates live-cell assay design from post-lysis protein preservation and provides practical selection and handling criteria.
-
IRG1–Itaconic Acid Control of TBK1 and IFN-I
2026-09-07
This Cell Reports study identifies an IRG1–itaconic acid feedback axis that restrains excessive type I interferon signaling by alkylating TBK1 at Cys605 and disrupting TBK1 dimerization. Its mechanistic and chemical-inhibitor findings clarify how immunometabolism can limit hyperinflammation, while also offering a useful framework for designing protein-preserving workflows when studying signaling proteins in complex extracts.
-
Plant Cell Lysis Buffer for WB and IP Workflows
2026-09-07
Build native-state protein workflows for Western blotting, immunoprecipitation, and co-immunoprecipitation from plant or cross-species samples. This guide connects inhibitor-supported extraction with the MAPK10–KRT16 mechanism while clearly separating product-enabled sample preparation from disease-specific biological conclusions.
-
Z-DEVD-FMK: Reading Apoptosis Beyond Caspase-3
2026-09-05
Z-DEVD-FMK is more than a routine caspase-3 inhibitor: its irreversible, cell-permeable activity also intersects with broader caspase signaling and calpain-mediated proteolysis. This thought-leadership guide shows how translational researchers can use it to interpret apoptosis assays, validate melanoma findings, and design better neuroprotection studies without overstating pathway specificity.
-
AP2-M Regulates Babesia Asexual Replication
2026-09-04
This study identifies AP2-M, an Apicomplexan AP2-family transcription factor in Babesia sp. Xinjiang, as a regulator of genes associated with red blood cell invasion, merozoite morphology, and cell-cycle progression. By integrating CUT&Tag, RNA sequencing, proteomics, and single-cell RNA sequencing after AP2-M disruption, the authors connect DNA occupancy with parasite phenotypes and transcriptional state.
-
MG-262: Proteasome Inhibition Workflows
2026-09-04
MG-262 enables controlled, reversible disruption of proteasome chymotryptic activity for ubiquitin-proteasome, apoptosis, and cell-cycle experiments. This workflow connects acute proteostasis stress with the skeletal-muscle CMA findings reported in the reference study while clearly separating what MG-262 can test from what requires dedicated CMA assays.
-
E-64 in Salt-Sensitive Hypertension: Study Analysis
2026-09-03
The reference study tested whether chronic inhibition of cysteine cathepsins alters hypertension, albuminuria, kidney injury, or podocyte calcium handling in Dahl salt-sensitive rats. E-64 did not improve these endpoints under the experimental conditions, demonstrating that cathepsin activity may not be a dominant modifiable driver in this model despite evidence of target engagement.
-
MLN2238: Precision Proteasome β5 Inhibition
2026-09-03
MLN2238 enables controlled, reversible chymotrypsin-like proteasome inhibition for apoptosis, proteostasis, and drug-resistance studies. Its strong β5-site preference supports focused oncology assays, while carefully designed stress-response workflows extend its value to CRTC–CREB research.
-
LTI6426 Enhances Panobinostat in Multiple Myeloma
2026-09-02
The reference study shows that the protein disulfide isomerase inhibitor LTI6426 substantially improves panobinostat activity in multiple myeloma models, including a proteasome inhibitor-resistant setting. Its central contribution is a dose-sparing combination strategy linked to coordinated induction of the ER-stress effectors ATF3, DDIT3/CHOP, and DNAJB1.
-
Immunoproteasome Activation Reprograms Human TRIM5α
2026-09-02
Jimenez-Guardeño and colleagues show that interferon-α can activate human TRIM5α against HIV-1 by remodeling the immunoproteasome and accelerating TRIM5α turnover. Their siRNA, reporter-virus, and CRISPR validation strategy provides a useful framework for studying how cellular proteostasis regulates antiviral restriction factors.
-
Disulfiram at the Proteasome–Pyroptosis Interface
2026-09-01
Disulfiram is moving from a legacy anti-alcoholism medicine to a strategically useful research probe spanning copper-dependent proteasome biology, cancer cell death, and inflammasome signaling. This article examines what is established, what remains hypothesis-driven, and how translational researchers can design more informative studies.
-
Hypoxia, Immunometabolism, and Tumor Immune Escape
2026-09-01
This 2025 Cancer Letters review presents tumor hypoxia as a systems-level driver of metabolic competition, immune dysfunction, and immunosuppressive microenvironment formation. Its main practical contribution is a framework for connecting oxygen gradients, tumor and immune-cell metabolism, cellular communication, and therapeutic strategy design.